View in EDS HTML Full Text PDF Full Text

Open-label pilot study of injectable naltrexone for cannabis dependence.

Saved in:
Bibliographic Details
Title: Open-label pilot study of injectable naltrexone for cannabis dependence.
Authors: Notzon, Daniel P. (AUTHOR), Kelly, Meredith A. (AUTHOR), Choi, C. Jean (AUTHOR), Pavlicova, Martina (AUTHOR), Mahony, Amy L. (AUTHOR), Brooks, Daniel J. (AUTHOR), Mariani, John J. (AUTHOR), Levin, Frances R. (AUTHOR)
Source: American Journal of Drug & Alcohol Abuse. 2018, Vol. 44 Issue 6, p619-627. 9p.
Subjects: Naltrexone, Marijuana abuse, Drug therapy, Drug approval, Drug dosage, Pilot projects
Abstract: Background: There are no FDA-approved pharmacotherapies for cannabis use disorders (CUD), despite the evaluation of numerous medications. Notably, chronic dosing of oral naltrexone decreases self-administration of cannabis in human laboratory studies.Objectives: To test the feasibility of long-acting injectable naltrexone for the treatment of CUD, while obtaining preliminary safety and efficacy data.Methods: Twelve adult participants (seven male) meeting DSM-IV-TR criteria for cannabis dependence enrolled into an 8-week, open-label pilot study conducted at an academic treatment research clinic. They received 380 mg intramuscular injections of long-acting naltrexone on study day 1 and at the start of study week 5. Outcome measures included percentages of study completers and participants who received the second injection, frequency of adverse events (AEs), and cannabis consumption measured by average daily grams, dollars, and using days per week as measured by timeline follow-back and urine oral delta-9-tetrahydrocannabinol (THC) concentrations.Results: Of the 12 participants enrolled in the study, 9 completed the study and 6 received the second injection. There were no severe AEs but an unexpected AE led to the addition of supportive medications to the protocol. Number of cannabis use days per week significantly decreased over the course of the study (p = .001). Creatinine-corrected urine THC concentrations and average daily cannabis use per study week in grams and in dollars did not decrease over the course of the study.Conclusions: Long-acting injectable naltrexone is a feasible intervention for CUD worthy of further study in a placebo-controlled, double-blinded randomized clinical trial. [ABSTRACT FROM AUTHOR]
Copyright of American Journal of Drug & Alcohol Abuse is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 131695547
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Open-label pilot study of injectable naltrexone for cannabis dependence.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Notzon%2C+Daniel+P%2E%22">Notzon, Daniel P.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kelly%2C+Meredith+A%2E%22">Kelly, Meredith A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Choi%2C+C%2E+Jean%22">Choi, C. Jean</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pavlicova%2C+Martina%22">Pavlicova, Martina</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mahony%2C+Amy+L%2E%22">Mahony, Amy L.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Brooks%2C+Daniel+J%2E%22">Brooks, Daniel J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mariani%2C+John+J%2E%22">Mariani, John J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Levin%2C+Frances+R%2E%22">Levin, Frances R.</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22American+Journal+of+Drug+%26+Alcohol+Abuse%22">American Journal of Drug & Alcohol Abuse</searchLink>. 2018, Vol. 44 Issue 6, p619-627. 9p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Naltrexone%22">Naltrexone</searchLink><br /><searchLink fieldCode="DE" term="%22Marijuana+abuse%22">Marijuana abuse</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+therapy%22">Drug therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+approval%22">Drug approval</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+dosage%22">Drug dosage</searchLink><br /><searchLink fieldCode="DE" term="%22Pilot+projects%22">Pilot projects</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>There are no FDA-approved pharmacotherapies for cannabis use disorders (CUD), despite the evaluation of numerous medications. Notably, chronic dosing of oral naltrexone decreases self-administration of cannabis in human laboratory studies.<bold>Objectives: </bold>To test the feasibility of long-acting injectable naltrexone for the treatment of CUD, while obtaining preliminary safety and efficacy data.<bold>Methods: </bold>Twelve adult participants (seven male) meeting DSM-IV-TR criteria for cannabis dependence enrolled into an 8-week, open-label pilot study conducted at an academic treatment research clinic. They received 380 mg intramuscular injections of long-acting naltrexone on study day 1 and at the start of study week 5. Outcome measures included percentages of study completers and participants who received the second injection, frequency of adverse events (AEs), and cannabis consumption measured by average daily grams, dollars, and using days per week as measured by timeline follow-back and urine oral delta-9-tetrahydrocannabinol (THC) concentrations.<bold>Results: </bold>Of the 12 participants enrolled in the study, 9 completed the study and 6 received the second injection. There were no severe AEs but an unexpected AE led to the addition of supportive medications to the protocol. Number of cannabis use days per week significantly decreased over the course of the study (p = .001). Creatinine-corrected urine THC concentrations and average daily cannabis use per study week in grams and in dollars did not decrease over the course of the study.<bold>Conclusions: </bold>Long-acting injectable naltrexone is a feasible intervention for CUD worthy of further study in a placebo-controlled, double-blinded randomized clinical trial. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of American Journal of Drug & Alcohol Abuse is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=131695547
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/00952990.2017.1423321
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 619
    Subjects:
      – SubjectFull: Naltrexone
        Type: general
      – SubjectFull: Marijuana abuse
        Type: general
      – SubjectFull: Drug therapy
        Type: general
      – SubjectFull: Drug approval
        Type: general
      – SubjectFull: Drug dosage
        Type: general
      – SubjectFull: Pilot projects
        Type: general
    Titles:
      – TitleFull: Open-label pilot study of injectable naltrexone for cannabis dependence.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Notzon, Daniel P.
      – PersonEntity:
          Name:
            NameFull: Kelly, Meredith A.
      – PersonEntity:
          Name:
            NameFull: Choi, C. Jean
      – PersonEntity:
          Name:
            NameFull: Pavlicova, Martina
      – PersonEntity:
          Name:
            NameFull: Mahony, Amy L.
      – PersonEntity:
          Name:
            NameFull: Brooks, Daniel J.
      – PersonEntity:
          Name:
            NameFull: Mariani, John J.
      – PersonEntity:
          Name:
            NameFull: Levin, Frances R.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2018
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-print
              Value: 00952990
          Numbering:
            – Type: volume
              Value: 44
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: American Journal of Drug & Alcohol Abuse
              Type: main
ResultId 1